Swiss drugmaker Novartis to buy Avidity Biosciences for $12 billion

Swiss drugmaker Novartis agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion.

​ Swiss drugmaker Novartis agreed to acquire U.S. biotech firm Avidity Biosciences for about $12 billion. USA TODAY – Breaking News and Latest News Today Read More